Vertice Pharma announced the launch of Thyquidity (levothyroxine sodium) oral solution.

Thyquidity is indicated for the treatment of hypothyroidism – as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

It is also approved for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.


Continue Reading

The product is supplied in 100mL amber glass bottles containing 100mcg of levothyroxine sodium per 5mL. Thyquidity should be administered directly to the mouth using a calibrated oral syringe.

References

  1. Vertice launches Thyquidity™ (levothyroxine sodium) oral solution. [press release]. New Providence, NJ: Vertice Pharma; February 24, 2021. 
  2. Thyquidity [package insert]. New Providence, NJ: Vertice Pharma; 2021.

This article originally appeared on MPR